369372-47-4

Basic information

• Product Name: lopinavir+ritonavir
• Synonyms: lopinavir+ritonavir
• CAS NO: 369372-47-4
• Molecular Formula: C74H96N10O10S2
• Molecular Weight: 1349.74504
• Mol File: 369372-47-4.mol
• Article Data: 0

Chemical Properties

• Boiling Point: 947°C at 760 mmHg
• Flash Point: 526.6°C
• Appearance: /
• Vapor Pressure: 0mmHg at 25°C
• CAS DataBase Reference: lopinavir+ritonavir(CAS DataBase Reference)
• NIST Chemistry Reference: lopinavir+ritonavir(369372-47-4)
• EPA Substance Registry System: lopinavir+ritonavir(369372-47-4)

Safety Data

• Hazardous Substances Data: 369372-47-4(Hazardous Substances Data)

Usage

Clinical Use

Recently, the U.S. FDA has approved the release of lopinavir/ritonavir combination in patients who have not responded to other regimens for treatment of HIV. The product is available in a soft-gelatin capsule containing 133.3 mg of lopinavir and 33.3 mg of ritonavir as well as in oral solutions containing 80 mg/mL of lopinavir and 20 mg/mL of ritonavir. The small amount of ritonavir is not expected to have antiretroviral activity; rather, the ritonavir is meant to increase the plasma concentrations of lopinavir by inhibiting lopinavir's metabolism by CYP3A4 (ritonavir acts as a booster). These drugs, in combination with other antiretroviral agents, have been approved for use in adults as well as in patients between the ages of 6 months and 12 years. This is the first PI to be indicated for the very young.

InChI:InChI=1/C37H48N6O5S2.C37H48N4O5/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30;1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46);5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t28-,31-,32-,33-;30-,31-,32-,34-/m00/s1